5427-29-2

Basic information

• Product Name: methyl 2-hydroxy-4-phenylmethoxy-benzoate
• Synonyms: methyl 2-hydroxy-4-phenylmethoxy-benzoate
• CAS NO: 5427-29-2
• Molecular Formula: C₁₅H₁₄O₄
• Molecular Weight: 258.27
• Mol File: 5427-29-2.mol

Chemical Properties

• Melting Point: 102-104 °C
• Boiling Point: 404.8°C at 760 mmHg
• Flash Point: 150.7°C
• Appearance: /
• Density: 1.227g/cm³
• Vapor Pressure: 3.94E-07mmHg at 25°C
• Refractive Index: 1.59
• Solubility: Chloroform; Acetone
• PKA: 9.38±0.10(Predicted)
• CAS DataBase Reference: methyl 2-hydroxy-4-phenylmethoxy-benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-hydroxy-4-phenylmethoxy-benzoate(5427-29-2)
• EPA Substance Registry System: methyl 2-hydroxy-4-phenylmethoxy-benzoate(5427-29-2)

Safety Data

• Hazardous Substances Data: 5427-29-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 2-hydroxy-4-phenylmethoxy-benzoate is used as an intermediate in the synthesis of 4-Hydroxy Flecainide (H942485), which is an analogue of Flecainide (F390000). Flecainide is a Class I antiarrhythmic agent used to treat various types of arrhythmias, including atrial fibrillation and ventricular tachycardia. The ester group in methyl 2-hydroxy-4-phenylmethoxy-benzoate plays a vital role in the synthesis process, allowing for the formation of the desired pharmaceutical compound with potential therapeutic benefits.
In the pharmaceutical industry, methyl 2-hydroxy-4-phenylmethoxy-benzoate is used as a key building block for the development of new drugs and therapeutic agents. Its unique chemical structure allows for further functionalization and modification, enabling the creation of novel molecules with improved pharmacological properties and enhanced efficacy.
Additionally, the compound may also find applications in other industries, such as the chemical industry, where it can be used as a starting material for the synthesis of various specialty chemicals, dyes, and other related products. Its versatility and reactivity make it a valuable asset in the development of new materials and technologies.

InChI:InChI=1/C15H14O4/c1-18-15(17)13-8-7-12(9-14(13)16)19-10-11-5-3-2-4-6-11/h2-9,16H,10H2,1H3

Upstream product

• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 22393-62-0 BnBr 
• 89-86-1 4-hydroxysalicylic acid 
• 100-51-6 benzyl alcohol 
• 422566-44-7 methyl 4-benzyloxy-2-methoxymethyloxybenzoate 
• 1026824-07-6 methyl 4-benzyloxy-2-(4-methoxy-benzyloxy)benzoate 
• 85593-76-6 methyl 2,4-bis(benzyloxy)benzoate 
• 741698-99-7 methyl 4-benzyloxy-2-isopropoxybenzoate 
• 100-39-0 benzyl bromide 
• 584-08-7 potassium carbonate 
• 100-44-7 benzyl chloride 

Downstream Products

• 95449-68-6 4-Benzyloxy-2-(2-oxo-tetrahydro-furan-3-yloxy)-benzoic acid methyl ester 
• 193803-87-1 methyl 4-[(phenylmethyl)oxy]-2-{[(trifluoromethyl)sulfonyl]oxy}benzoate 
• 5448-45-3 4-(benzyloxy)-2-hydroxybenzoic acid 
• 179995-47-2 4-benzyloxy-2-(4-bromobutoxy)-benzoic acid methyl ester 
• 741698-99-7 methyl 4-benzyloxy-2-isopropoxybenzoate 
• 422566-44-7 methyl 4-benzyloxy-2-methoxymethyloxybenzoate 
• 1026824-07-6 methyl 4-benzyloxy-2-(4-methoxy-benzyloxy)benzoate 
• 1381865-06-0 C₂₃H₂₀O₃ 
• 1381865-07-1 C₂₅H₂₀Cl₂O₄ 
• 1381865-08-2 C₂₅H₂₂O₄ 
• 1381865-09-3 C₂₅H₂₂F₂O₃ 
• 1381865-10-6 C₁₈H₁₆F₂O₃ 
• 1381864-81-8 C₂₈H₂₃F₂NO₃ 

Relevant articles and documents

COMPOUNDS AND THEIR USES AS MIF INHIBITORS

The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the i

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

Identification of a bacteria-produced benzisoxazole with antibiotic activity against multi-drug resistant Acinetobacter baumannii

The emergence of multi-drug resistant pathogenic bacteria represents a serious and growing threat to national healthcare systems. Most pressing is an immediate need for the development of novel antibacterial agents to treat Gram-negative multi-drug resistant infections, including the opportunistic, hospital-derived pathogen, Acinetobacter baumannii. Herein we report a naturally occurring 1,2-benzisoxazole with minimum inhibitory concentrations as low as 6.25 μg ml?1 against clinical strains of multi-drug resistant A. baumannii and investigate its possible mechanisms of action. This molecule represents a new chemotype for antibacterial agents against A. baumannii and is easily accessed in two steps via de novo synthesis. In vitro testing of structural analogs suggest that the natural compound may already be optimized for activity against this pathogen. Our results demonstrate that supplementation of 4-hydroxybenzoate in minimal media was able to reverse 1,2-benzisoxazole’s antibacterial effects in A. baumannii. A search of metabolic pathways involving 4-hydroxybenzoate coupled with molecular modeling studies implicates two enzymes, chorismate pyruvate-lyase and 4-hydroxybenzoate octaprenyltransferase, as promising leads for the target of 3,6-dihydroxy-1,2-benzisoxazole.

BENZOATE COMPOUND

The present invention provides a benzoic acid ester compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. A compound represented by the formula (I) or a salt thereof has an enteropeptidase inhibitory effect and is useful as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like: [in the formula, each symbol is as defined in the specification].

Identification of N-Hydroxycinnamamide analogues and their bio-evaluation against breast cancer cell lines

The present study demonstrates the identification of N-hydroxycinnamamide derivatives and their anticancer potential against human triple-negative breast cancer cell line MDA-MB?231, MCF-7 and non-malignant origin cell line, HEK-293 (human embryonic kidney). MTT assay was studied with HEK-293 cell line. Anticancer potential of the N-hydroxycinnamamide derivatives were compared with marked drug Tamoxifen through in vitro study. The compound numbers 3b and 3h exhibit most potent activity against antagonistic breast cancer cells (MDA-MB-231) with IC50 13μM and 5μM respectively. Compound 3h promotes DNA fragmentation and induction of apoptosis. Furthermore, loss of mitochondrial membrane potential induced by compound 3h. The major mechanism of compound 3h for anti-breast cancer activity was probably initiation of reactive oxygen species (ROS) in cancer cells thereby persuading apoptotic cell deaths in cancer cells.

NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity

A series of phenoxybutanoic acid derivatives were synthesized and tested for their antagonistic activity on the contraction of the rat thoracic aortic ring induced by endothelin-1. Preliminary screening results showed that 6e and 6g with benzoheterocycles demonstrated significant antagonistic activities when compared to the reference compound BQ123. The results from additional assays for the binding affinity and selectivity for endothelin receptors showed that 6e was a selective ETA antagonist with a nanomolar IC50. Moreover, 6e was effective in relieving hypoxia-induced pulmonary arterial hypertension and right ventricular weight ratio. Therefore, 6e may have potential for further development as a therapeutic agent for the treatment of cardiovascular diseases.

1 -HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS

Provided are compounds useful for controlling endoparasites both in animals and agriculture. Further provided are methods for controlling endoparasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling endoparasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. The claimed compounds are described by the following Markush formula:A typical example for a compound according to above formula is: A typical example for a compound according to above formula is:

Synthesis of toxyloxanthone B

A synthesis of the naturally occurring xanthone toxyloxanthone B is described, in which the key step is the regioselective addition of a methyl salicylate to a substituted benzyne, followed by cyclization of the intermediate aryl anion to form the xanthon

Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat

Sodium-hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed transmembrane ion channel responsible for intracellular pH regulation. During myocardial ischemia, low pH activates NHE1 and causes increased intracellular calcium levels and aberrant cellular processes, leading to myocardial stunning, arrhythmias, and ultimately cell damage and death. The role of NHE1 in cardiac injury has prompted interest in the development of NHE1 inhibitors for the treatment of heart failure. This report outlines our efforts to identify a compound suitable for once daily, oral administration with low drug-drug interaction potential starting from NHE1 inhibitor sabiporide. Substitution of a piperidine for the piperazine of sabiporide followed by replacement of the pyrrole moiety and subsequent optimization to improve potency and eliminate off-target activities resulted in the identification of N-[4-(1-acetyl- piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine (60). Pharmacological evaluation of 60 revealed a remarkable ability to prevent ischemic damage in an ex vivo model of ischemia reperfusion injury in isolated rat hearts.